ImmuCell Swings to Profit on Strong Sales, Margin Expansion

TL;DR

**ICCC is finally turning the corner with strong sales and profit, but watch out for those pesky contamination issues.**

AI Summary

ImmuCell Corporation reported a significant turnaround, achieving net income of $1,948,863 for the six-month period ended June 30, 2025, a substantial improvement from a net loss of $1,969,494 in the prior-year period. Product sales increased by 14% to $14,512,054 for the six months ended June 30, 2025, up from $12,730,467 in the same period of 2024. Gross margin more than doubled to $6,171,896 from $3,525,845, driven by a decrease in costs of goods sold from $9,204,622 to $8,340,158. The company's cash and cash equivalents rose to $5,998,494 as of June 30, 2025, from $3,758,232 at December 31, 2024. Operating expenses decreased by 14% to $4,484,709 for the six months ended June 30, 2025, compared to $5,212,505 in the prior year, primarily due to reduced product development and sales and marketing expenses. A key risk highlighted is the dependence on the successful development and regulatory approval of new products like Re-Tain, alongside ongoing challenges with production contamination events, with one occurring in Q2 2025. The strategic outlook focuses on leveraging its First Defense product line and advancing Re-Tain, a potential first-of-its-kind animal drug.

Why It Matters

This filing signals a crucial turning point for ImmuCell, moving from significant losses to profitability, which could attract new investors and stabilize its financial position. The substantial increase in product sales and gross margin demonstrates improved operational efficiency and market acceptance of its First Defense line, potentially strengthening its competitive stance against larger animal health companies. For employees, this financial health could mean greater job security and potential for growth. Customers benefit from a more stable supplier of critical animal health products. The successful development of Re-Tain, a non-antibiotic mastitis treatment, could disrupt the dairy industry by offering a novel solution to a pervasive problem, reducing reliance on human-use antibiotics and potentially creating a new market segment.

Risk Assessment

Risk Level: medium — The company faces medium risk due to ongoing production contamination events, with one occurring in Q2 2025, which previously led to a production slowdown in 2023 and lower sales. Additionally, a significant portion of assets, $25,259,990, is tied to the Re-Tain project, which is still awaiting regulatory approval, posing a substantial development and market risk.

Analyst Insight

Investors should consider ICCC as a speculative growth opportunity given its recent swing to profitability and the potential of its Re-Tain product. However, they must closely monitor future filings for updates on production stability and Re-Tain's regulatory progress, as these are critical for sustained success.

Financial Highlights

debt To Equity

0.56

revenue

$14,512,054

operating Margin

11.63%

total Assets

$46,720,898

total Debt

$9,798,662

net Income

$1,948,863

eps

$0.22

gross Margin

42.53%

cash Position

$5,998,494

revenue Growth

+14%

Revenue Breakdown

Key Numbers

• $1.95M — Net Income (Swung from a $1.97M net loss in the prior six-month period to a $1.95M net income for the six months ended June 30, 2025.)
• $14.51M — Product Sales (Increased by 14% from $12.73M in the prior six-month period to $14.51M for the six months ended June 30, 2025.)
• $6.17M — Gross Margin (More than doubled from $3.53M in the prior six-month period to $6.17M for the six months ended June 30, 2025.)
• $5.99M — Cash and Cash Equivalents (Increased by $2.24M from $3.76M at December 31, 2024, to $5.99M as of June 30, 2025.)
• $0.22 — Basic Net Income Per Share (Improved from a loss of $0.25 per share in the prior six-month period to an income of $0.22 per share for the six months ended June 30, 2025.)
• $25.26M — Re-Tain Assets (Represents the total investment in land, buildings, and equipment for the Re-Tain project as of June 30, 2025.)

Key Players & Entities

• ImmuCell Corporation (company) — registrant
• First Defense (company) — product line
• Re-Tain (company) — developing product
• U.S. Department of Agriculture (regulator) — governing regulatory authority for veterinary biologics
• U.S. Food and Drug Administration (regulator) — governing regulatory authority for new animal drugs
• $1,948,863 (dollar_amount) — net income for six months ended June 30, 2025
• $14,512,054 (dollar_amount) — product sales for six months ended June 30, 2025
• $6,171,896 (dollar_amount) — gross margin for six months ended June 30, 2025
• $5,998,494 (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $25,259,990 (dollar_amount) — total Re-Tain assets as of June 30, 2025

FAQ

Risk Factors

• Production Contamination Events [high — operational]: The company experienced a production contamination event in Q2 2025, which poses an ongoing risk to product quality and supply. Such events can lead to product recalls, reputational damage, and financial losses.
• New Product Development and Approval [high — regulatory]: ImmuCell's future growth is significantly dependent on the successful development and regulatory approval of new products, such as Re-Tain. Delays or failures in this process could hinder revenue growth and market expansion.
• Dependence on Key Products [medium — financial]: While the company is diversifying, there remains a reliance on the performance of its existing product lines, particularly First Defense. Any adverse market shifts or competitive pressures affecting these core products could impact financial results.

Industry Context

ImmuCell operates in the animal health sector, focusing on novel biologics for livestock. The industry is characterized by increasing demand for animal welfare and productivity, driving innovation in disease prevention and treatment. Key trends include the development of targeted therapies and the need for regulatory compliance for new animal drugs.

Regulatory Implications

The development and commercialization of new animal drugs like Re-Tain are subject to stringent regulatory approval processes by agencies such as the FDA. Delays or failures in obtaining these approvals can significantly impact market entry and financial performance. Compliance with manufacturing standards is also critical to avoid product recalls.

What Investors Should Do

1. Monitor Re-Tain development progress and regulatory milestones.
2. Assess the impact of production contamination events on operational stability and costs.
3. Evaluate the sustainability of improved gross margins and reduced operating expenses.

Key Dates

• 2025-06-30: End of Six-Month Period — Reported significant financial turnaround with net income of $1.95M and 14% revenue growth to $14.51M.
• 2025-06-30: Production Contamination Event — A production contamination event occurred in Q2 2025, highlighting ongoing operational risks.
• 2025-12-31: Previous Year-End — Provided a baseline for comparison, with cash and cash equivalents at $3,758,232.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (ImmuCell's accumulated deficit decreased from $(14,163,726) to $(12,214,863), reflecting the recent profitability.)

Cost of goods sold (COGS)

The direct costs attributable to the production or purchase of the goods sold by a company. (A decrease in COGS from $9,204,622 to $8,340,158 significantly contributed to the improved gross margin.)

Gross margin

The difference between revenue and cost of goods sold, expressed as a percentage of revenue. (More than doubled to $6,171,896 (42.53%), indicating improved production efficiency or pricing power.)

Net operating income (loss)

Profitability from a company's core business operations before accounting for interest and taxes. (Swung from a loss of $(1,686,660) to income of $1,687,187, showing operational recovery.)

Re-Tain

A potential first-of-its-kind animal drug being developed by ImmuCell. (Represents a key strategic focus and future growth driver for the company, with significant investment in related assets.)

Year-Over-Year Comparison

Compared to the six-month period ended June 30, 2024, ImmuCell has demonstrated a substantial financial turnaround. Product sales increased by 14% to $14.51 million, while gross margin more than doubled to $6.17 million due to a decrease in the cost of goods sold. Operating expenses were reduced by 14%, contributing to a swing from a net loss of $1.97 million to a net income of $1.95 million. Cash reserves also saw a healthy increase.

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 par value per share ICCC The Nasdaq Cap

Filing Documents

• ea0252758-10q_immucell.htm (10-Q) — 1136KB
• ea025275801ex31-1_immucell.htm (EX-31.1) — 7KB
• ea025275801ex31-2_immucell.htm (EX-31.2) — 7KB
• ea025275801ex32-1_immucell.htm (EX-32.1) — 4KB
• ea025275801ex32-2_immucell.htm (EX-32.2) — 4KB
• 0001213900-25-076635.txt ( ) — 7163KB
• iccc-20250630.xsd (EX-101.SCH) — 57KB
• iccc-20250630_cal.xml (EX-101.CAL) — 41KB
• iccc-20250630_def.xml (EX-101.DEF) — 300KB
• iccc-20250630_lab.xml (EX-101.LAB) — 550KB
• iccc-20250630_pre.xml (EX-101.PRE) — 325KB
• ea0252758-10q_immucell_htm.xml (XML) — 1026KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION ITEM 1. Unaudited Financial Statements Balance Sheets as of June 30, 2025 and December 31, 2024 1 2 3 4-5 Notes to Unaudited Financial Statements 6-23 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24-39 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 39 ITEM 4.

Controls and Procedures

Controls and Procedures 39

: OTHER INFORMATION

PART II: OTHER INFORMATION

THROUGH 6

ITEM 1 THROUGH 6 . 40-49

Signatures

Signatures 50 i ImmuCell Corporation Part 1. FINANCIAL INFORMATION

UNAUDITED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED FINANCIAL STATEMENTS BALANCE SHEETS (Unaudited) As of June 30, 2025 As of December 31, 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 5,998,494 $ 3,758,232 Trade accounts receivable 2,378,823 3,771,133 Inventory 8,294,426 7,112,623 Prepaid expenses and other current assets 464,566 400,762 Total current assets 17,136,309 15,042,750 Property, plant and equipment, net 24,882,998 25,349,019 Operating lease right-of-use asset 4,542,863 4,560,679 Goodwill 95,557 95,557 Intangible assets, net 9,552 19,104 Other assets 53,619 33,368 TOTAL ASSETS $ 46,720,898 $ 45,100,477 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current portion of debt obligations $ 1,535,439 $ 1,497,619 Current portion of operating lease liability 322,753 432,072 Accounts payable and accrued expenses 2,588,223 2,482,522 Total current liabilities 4,446,415 4,412,213 LONG-TERM LIABILITIES: Debt obligations, net of current portion 8,263,223 9,040,975 Operating lease liability, net of current portion 4,143,832 4,129,102 Total long-term liabilities 12,407,055 13,170,077 TOTAL LIABILITIES 16,853,470 17,582,290 CONTINGENT LIABILITIES AND COMMITMENTS (See Note 10) STOCKHOLDERS' EQUITY: Common stock, $ 0.10 par value per share, 15,000,000 and 15,000,000 shares authorized, 9,105,622 and 9,042,392 shares issued and 9,045,851 and 8,979,091 shares outstanding, as of June 30, 2025 and December 31, 2024, respectively. 910,563 904,240 Additional paid-in capital 41,302,488 40,916,155 Accumulated deficit ( 12,214,863 ) ( 14,163,726 ) Treasury stock, at cost, 59,771 and 63,301 shares as of June 30, 2025 and December 31, 2024, respectively ( 130,760 ) ( 138,482 ) TOTAL STOCKHOLDERS' EQUITY 29,867,428 27,518,187 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 46,720,898 $ 45,100,477 The accompanying notes are an integral part of these unaudited financial statement

View Full Filing

View this 10-Q filing on SEC EDGAR